pc_lang

Secretariat

Department of Cardiovascular Surgery
Tokyo Medical University
6-7-1 Nishishinjuku Shinjuku-ku Tokyo
160-0023 Japan

Congress Secretariat

c/o Japan Convention Services, Inc.
14F Daido Seimei Kasumigaseki Bldg.
1-4-2 Kasumigaseki Chiyodaku Tokyo
100-0013 Japan
TEL: +81-3-3508-1214
FAX: +81-3-3508-1302
E-mail: 48jsvs[A]convention[D]co[D]jp( Please chainge [A] to @ [D] to . )

Call for Abstracts

Abstract Submission Period

Friday, November 15, 2019 – Monday, January 6, 2020 [Closed]
Thank you for abstract submission.

Submission guidelines

The submission period for the 48th annual meeting will not be extended as the period is longer than usual. Please submit your abstracts within the deadline.
You will not be able to register, modify, or delete your abstract proposal after the deadline.
After submission closure, no change in your abstract proposal including coauthor is accepted.

Types of presentations for submission

Session Theme of session
Symposium
(Partially from public call)

Abstract
English

Presentation
English is recommended.

Slides
English

Video
Required

  1. State-of-the-art treatment for acute type A dissection: malperfusion, IMH, root replacement, arch replacement with ET/FET, anastomotic technique, TEVAR, etc

    Session outline

    This session will extensively discuss the current status and the future of the state-of-the-art treatments for acute type A aortic dissection in Japan and other countries, including abstracts on malperfusion of the coronary and carotid arteries, indication of surgery for IMH (non-communicating aortic dissection), indications and techniques for aortic root replacement and arch replacement (ET/FET), merits and demerits of FET, anastomotic techniques and application of ascending TEVAR.

  2. State-of-the-art aortic root/valve repair: genetic aortic disease, bicuspid aortic valve, valve sparing root replacement, Bentall operation, etc.

    Session outline

    This session will extensively discuss the state-of-the-art root replacement techniques. The main topic of discussion is valve-sparing aortic root replacement (+/- valvuloplasty) for genetic aortic disease and bicuspid aortic valve. The session also covers aortic root replacement for severe IE associated with inflammatory aortic disease or annular abscess and the recently reported Bio-Bentall procedure.

  3. State-of-the-art aortic arch repair: open, hybrid, or total endografting

    Session outline

    This session will discuss total arch replacement, a common aortic surgery, in terms of the procedures and outcomes of open repair, hybrid repair and stent grafting. We also invite abstracts on brain protection and new devices.

  4. State-of-the-art descending aortic/thoracoabdominal aortic repair: open, hybrid, or total endografting

    Session outline

    This session will discuss the procedures and outcomes of open repair, hybrid repair and stent grafting for lesions of the descending thoracic aorta and the thoracoabdominal aorta, including abstracts on spine protection and new devices.

  5. State-of-the-art treatment for acute, subacute, and chronic type B dissection: open, hybrid, or total endografting

    Session outline

    This session will discuss open repair (including FET), hybrid repair and stent grafting for complicated/uncomplicated acute/subacute type B aortic dissection and chronic type B dissection.

  6. State-of-the-art treatments for infected thoracic aneurysm, infected prostheses, and aorto-esophageal/bronchial fistulae

    Session outline

    This session will discuss the indications, procedures and outcomes of surgery for infected thoracic aortic aneurysm, vascular graft infection, and aortoesophageal and aortopulmonary fistulae that are extremely difficult to treat.

  7. Aggressive endovascular or open surgical treatment after TEVAR

    Session outline

    This session will discuss the indications, procedures and outcomes of endovascular treatment and surgery for complications after TEVAR (+FET).

  8. Management of abdominal aortic and iliac aneurysms with complex anatomy: suprarenal AAA, short/angulated neck AAA, access root stenosis, or bilateral IAAs

    Session outline

    Favorable short-term and long-term outcomes can be achieved if EVAR is performed in compliance with IFU. However, many high-risk patients who cannot undergo open surgery can be treated by EVAR although EVAR in such patients is off-label. In this session, the potential of EVAR for patients with challenging anatomy such as pararenal abdominal aortic aneurysm, highly angulated neck, poor accessibility (severe aortic narrowing) and bilateral internal iliac aneurysm will be discussed.

  9. The mystery of aneurysm sac shrinkage: why sac shrinkage does not always occur following EVAR?

    Session outline

    Decrease in aneurysm size is an ideal EVAR outcome, but EVAR does not always decrease the size of an aneurysm. Factors associated with downsizing of the aneurysm include type II endoleak, endotension, graft, diameter of the aneurism, calcification of the aneurysm, thrombus in the aneurysm, inflammation, smoking, diabetes, hypertension and antithrombotic agents, but none of them are decisive. This session will discuss the possible mechanisms behind the inability of EVAR to decrease aneurysm size in all cases.

  10. Open AAA repair in the EVAR era: technical expertise including open conversion after EVAR

    Session outline

    Since EVAR has become a common procedure for abdominal aortic aneurysm, open surgery is now indicated for patients for whom EVAR is difficult or those requiring repeat surgery after EVAR. Therefore, open surgery currently requires high level of skill. In this session, a video on high skill of open surgery (including open conversion) will be shown to discuss what is necessary to acquire such a skill.

  11. Open or endovascular repair for ruptured AAA

    Session outline

    Many observational studies and comparative studies using database records have reported that EVAR reduces mortality in cases with ruptured abdominal aortic aneurysm (AAA). Unexpectedly, however, previous randomized controlled trials have not demonstrated the superiority of EVAR over prosthetic graft replacement surgery (open surgery). In this context, this session will discuss the current strategies, challenges, and future perspectives of treatment for ruptured AAA.

  12. Aggressive endovascular or surgical treatment for endoleaks after EVAR

    Session outline

    Endoleak is an EVAR-specific complication that may lead to aneurysm enlargement or rupture and requires appropriate treatment. Although various kinds of endovascular and surgical treatments have been performed for endoleaks, their outcomes are not definitive. In this session, a video showing the currently employed interventions is presented and the reason of selection of each treatment and the ability of those treatments to improve the prognosis of the condition are discussed.

  13. Therapeutic options for chronic limb-threatening ischemia: open surgery, EVT, or regenerative therapy?

    Session outline

    Vascular diseases in the lower legs and feet remain a topic of discussion and debate, as apparent from the case wherein critical limb ischemia (CLI) was renamed chronic limb-threatening ischemia (CLTI).
    We invite abstracts on a wide-range of pathologies and treatment options, including bypass surgery, endovascular treatment and regenerative medicine.

  14. Endovascular therapies for venous diseases

    Session outline

    Post-thrombotic syndrome (PTS) is a troubling complication that often occurs in the chronic phase of deep vein thrombosis (DVT). Despite receiving an appropriate anticoagulant therapy, 20–50% of patients with DVT develop PTS. Conventionally, conservative therapy with compression stockings has been performed for PTS. Since a venous stent has recently been approved in the United States, endovascular treatment for PTS has been spreading as an on-label treatment. This session will discuss the future direction of PTS prevention and treatment.

  15. Surgical, medical, or hybrid repair for PE/CTEPH

    Session outline

    This session will discuss surgical, medical and hybrid treatments for acute pulmonary embolism and chronic thromboembolic pulmonary hypertension/chronic thromboembolic disease (CTEPH/CTED).

  16. Safety and efficacy of paclitaxel-coated stents and balloons: Criteria for the use of paclitaxel devices

    Session outline

    The FDA suggests that the use of a paclitaxel-coated balloon (DCB) or paclitaxel-eluting stent (DCS) to treat peripheral arterial disease (PAD) in the lower extremities increases the long-term mortality of patients. In this session, speakers will present their experiences with DCB and DCS and discuss the criteria for their use.

Special program

Abstract
English

Presentation
English

Slides
English

Symposium of women doctors
Work style reform from the perspective of women doctors — No wind, tailwind or headwind?

Session outline

The Japanese government is promoting “work style reform” to improve the work environment. It aims to overcome the issues due to the following factors: decrease in the labor population caused by a decline in the birthrate and aging of the population; health problems due to long working hours; and restriction of workstyle due to childbirth, childcare, and nursing care. These backgrounds directly affect women doctors more than their male counterparts. Speakers are expected to voice their opinions on the work style reform and their suggestions for the same.

General presentation
(Oral & poster)
(Public call)

Abstract
English

Presentation
English

Slides
English

  1. Acute type A aortic dissection
  2. Chronic type A aortic dissection
  3. Acute type B aortic dissection
  4. Chronic type B aortic dissection
  5. Ruptured thoracic aortic aneurysm
  6. Ruptured abdominal aortic aneurysm
  7. Thoracic aortic aneurysm (TEVAR)
  8. Thoracic aortic aneurysm (hybrid repair)
  9. Thoracic aortic aneurysm (root, ascending)
  10. Thoracic aortic aneurysm (arch)
  11. Thoracic aortic aneurysm (descending)
  12. Thoracoabdominal aortic aneurysm
  13. Thoracoabdominal aortic aneurysm (TEVAR, hybrid repair)
  14. Infected thoracic aortic aneurysm
  15. Thoracic aorta — aortoesophageal / bronchial fistulae
  16. Pararenal abdominal aortic aneurysm
  17. Abdominal aortic aneurysm
  18. Abdominal aortic aneurysm (EVAR)
  19. Infected abdominal aortic aneurysm
  20. Abdominal aorta — aortoduodenal fistula
  21. Abdominal visceral arteries
  22. Iliac aneurysm
  23. Aortoiliac occlusive disease
  24. Arteries of the lower limbs (femoropopliteal artery)
  25. Arteries of the lower limbs (lower legs)
  26. Peripheral arteries (others)
  27. Peripheral aneurysm
  28. Blood access (vascular access)
  29. Carotid arteries
  30. Varicosis
  31. Deep vein thrombosis
  32. Acute and chronic pulmonary embolism
  33. Pulmonary artery (others)
  34. Venous diseases (others)
  35. Lymphatic vessels
  36. Revascularization
  37. Intraoperative/postoperative management, postoperative complications
  38. Examinations and diagnosis
  39. Experiments, basic medicine
  40. Nursing
  41. Other healthcare professionals (general topics)
  42. Others
  • Please note that we may ask you to revise the format of presentation for convenience and uniformity of structure.
  • Rejected abstracts for symposium will be re-examined to determine their suitability for the general presentations category. This will be decided by the president on the review by the program organizing committee.
  • Abstracts that have been registered as general presentations may be included in the symposium if deemed suitable by the president.
  • General presentations will be presented in either of the following presentation sessions. Please select your session of choice for the presentation.

    (1) Oral presentation

    Time for presentation
    (minutes)
    Time for discussion
    (minutes)
    Video
    Oral Presentation 8 4 Required
    Surgical Forum 5 3 Preferable
    Case Report 3 2 Preferable

    (2) Poster presentation

  • The format of presentation for the “general presentations” category will be determined by the president based on the review by the program organizing committee.

How to submit

Please download an abstract submission form (word file) from below and send the filled form to the congress secretariat (48jsvs[A]convention[D]co[D]jp( Please chainge [A] to @ [D] to . )).
The abstract submitted by any other way will not be accepted.

Abstract Submission Form

Abstract Format:

  • Abstract including title, all author’s names, all author institutions and abstract body should be within 2200 characters or less in length.
  • The number of institutions to be registered should be less than 10 institutions.

IMPORTANT — Disclosure of conflict of interest

Regardless of whether or not there is any conflict of interest, all presenters are required to disclose the conflict of interest information pertaining to a 3-year period before the day of abstract submission and a certain period until the day of presentation.

Please download the COI slide format from here. It must also be disclosed on the last slide of the presentation or at the bottom of the poster to be presented.

Registered personal information will be used exclusively for the purpose of organizing the 48th Annual Meeting of the Japanese Society for Vascular Surgery and will be strictly controlled with a necessary security measure.

Acceptance or rejection of abstracts

Please note that the acceptance or rejection of presentation abstracts is left to the president’s discretion.
The acceptance or rejection notice will be sent to your registered email address in early March.

Contact

Congress Secretariat of the 48th Annual Meeting of the Japanese Society for Vascular Surgery
Japan Convention Services, Inc.
Address: 14th floor of the Daido Seimei Kasumigaseki Building
1-4-2 Kasumigaseki, Chiyoda-ku, Tokyo 100-0013
TEL: +81-3-3508-1214   FAX: +81-03-3508-1302
E-mail: 48jsvs[A]convention[D]co[D]jp( Please chainge [A] to @ [D] to . )

Page top